Markets:

Overview

News

Currencies

International

Treasuries

Biogen Idec (NQ:BIIB)

171.14 -4.60 (-2.62%)

Streaming Delayed Price Updated: 3:03 PM EST, Dec 16, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2

...

13 14 15 16 17 18 19 20 21

...

56 57 Next >

The Law Offices of Frank R. Cruz Announces Investigation of Biogen Inc. (BIIB) on Behalf of Investors

February 21, 2024

From The Law Offices of Frank R. Cruz

Via Business Wire

Peering Into Biogen's Recent Short Interest ↗

February 19, 2024

Via Benzinga

From Zero to Hero: 7 Stock Losers That Could Turn Things Around in 2024 ↗

February 19, 2024

Although these companies suffered earlier, they could become stock turnarounds as investors recognize their potential.

Via InvestorPlace

7 Contrarian Biotech Stocks to Consider Amid Sector Weakness ↗

February 15, 2024

Although the healthcare innovation space has struggled recently, these contrarian biotech stocks now offer compelling discounts.

Via InvestorPlace

Breaking Down Biogen: 8 Analysts Share Their Views ↗

February 13, 2024

Via Benzinga

Biogen Slumps As Aduhelm Costs Squeeze Fourth-Quarter Profit ↗

February 13, 2024

The company missed both sales and earnings expectations for the fourth quarter.

Via Investor's Business Daily

Looking At Biogen's Recent Unusual Options Activity ↗

February 12, 2024

Via Benzinga

Here's How Much You Would Have Made Owning Biogen Stock In The Last 20 Years ↗

February 09, 2024

Via Benzinga

Biogen Could Engage In $1B-$2B Deals To Fill Revenue Shortfall Gaps, Analyst Says ↗

February 14, 2024

Biogen's Leqembi launch challenges impact stock growth; Spinraza faces competition. Analyst lowers price target to $316, citing uncertainties.

Via Benzinga

Citigroup To Rally Over 19%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

February 14, 2024

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

Biogen (BIIB) Q4 2023 Earnings Call Transcript ↗

February 13, 2024

BIIB earnings call for the period ending December 31, 2023.

Via The Motley Fool

Topics Earnings

Markets Tumble, VIX Up 8% On Hot Inflation Data, Dollar, Yields Jump As Traders Unwind Rate Cut Bets: What's Driving Markets Tuesday? ↗

February 13, 2024

Wall Street witnessed one of the worst sessions since the beginning of the year, with widespread declines across the board as stocks were hit by the impact of a higher-than-expected inflation report.

Via Benzinga

Topics Economy Stocks

Critical Insights From Biogen Analyst Ratings: What You Need To Know ↗

January 24, 2024

Via Benzinga

$1000 Invested In This Stock 20 Years Ago Would Be Worth $6,100 Today ↗

January 11, 2024

Via Benzinga

Why Is Biogen Stock Trading Lower On Tuesday? ↗

February 13, 2024

Biogen's Q4 2023 performance, with $2.39 billion in sales, adjusted EPS of $2.95, and updates on key drugs.

Via Benzinga

Nasdaq, S&P 500 Set For Weaker Open As Traders Keep Eyes Peeled On Inflation Data: Analyst Flags Key CPI Report Item To Watch ↗

February 13, 2024

Despite the Fed rhetoric about the inflation fight being still on, the central bank will likely cut rates this year, an analyst said.

Via Benzinga

Topics Economy Stocks

Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia

February 12, 2024

From Biogen Inc.

Via GlobeNewswire

Comparing Biogen With Industry Competitors In Biotechnology Industry ↗

January 10, 2024

Via Benzinga

Earnings Scheduled For February 13, 2024 ↗

February 13, 2024

Companies Reporting Before The Bell • LCI Indus (NYSE:LCII) is likely to report quarterly earnings at $0.18 per share on revenue of $838.27 million.

Via Benzinga

3 Millionaire-Maker Stocks to Buy While the Gettin’ Is Good ↗

February 12, 2024

For patient, long-term investors, these three underestimated names can easily become millionaire-maker stocks.

Via InvestorPlace

7 Biotech Stocks Fighting America’s Deadliest Diseases ↗

February 08, 2024

Although the human condition can be alarmingly frail at times, these groundbreaking biotech stocks are aiming to right the ship.

Via InvestorPlace

Biogen Gives Up On Aduhelm Efforts After Two Years Of Controversial FDA Accelerated Approval For Alzheimer's, Shifts Focus On Newer Medicines ↗

January 31, 2024

Latest on Biogen's decision to discontinue Aduhelm, its Alzheimer's drug, following controversial FDA approval.

Via Benzinga

Biogen to Realign Resources for Alzheimer's Disease Franchise

January 31, 2024

From Biogen Inc.

Via GlobeNewswire

NeuroSense's (NASDAQ: NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024 ↗

January 29, 2024

Amyotrophic lateral sclerosis (ALS) is a progressive neurological disease that kills the nerve cells controlling the voluntary movement of muscles. It is incurable and results in complete paralysis and...

Via Benzinga

AT&T To Rally Around 44%? Here Are 10 Top Analyst Forecasts For Thursday ↗

January 25, 2024

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

Slow Market Penetration For Biogen's Another Alzheimer's Drug: UBS Highlights Risks, Forecasts ↗

January 24, 2024

UBS insights on Biogen Inc's challenges with Leqembi in the Alzheimer's market. Analyst downgrades, revised sales estimates, and CEO's growth strategy.

Via Benzinga

Highlights From the 2024 JPMorgan Health Care Conference ↗

January 22, 2024

Weight loss drugs are taking center spotlight, but other developing treatments could change how we live.

Via The Motley Fool

These Could Be the Biggest Nasdaq-100 Winners in 2024, According to Wall Street ↗

January 18, 2024

Nice gains could be on the way for three stocks if analysts are right.

Via The Motley Fool

Evolving Landscape For Alzheimer's Blood Tests Gains Momentum Amid Inaccuracy Concerns ↗

January 12, 2024

A less invasive alternative to PET scans, these tests offer quick identification for emerging treatments. Learn more about the latest advancements in Alzheimer's detection.

Via Benzinga

Analyst Assesses Cell-Programming Focused Ginkgo Bioworks' Positioning Amid Revenue Surge, Program Adjustments ↗

January 10, 2024

Wednesday, Ginkgo Bioworks Holdings Inc (NYSE: DNA) released preliminary FY23 sales of $250 million-$260 million, compared to the consensus of $258.65 million.

Via Benzinga

< Previous 1 2

...

13 14 15 16 17 18 19 20 21

...

56 57 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.